Showing 4651-4660 of 7282 results for "".
- ZORYVE Cream 0.15% for AD Commercially Available This Weekhttps://practicaldermatology.com/news/zoryve-cream-015-ad-commercially-available-week/2467570/Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild-to-moderate atopic dermatitis in adults and children down to age 6 in the United States, along with a co-promotion agreement with Kowa Pharmaceuticals America, Inc. ZORYVE is a o
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu
- FDA Approves Deuruxolitinib for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-deuruxolitinib-alopecia-areata/2467563/The U.S. Food and Drug Administration (FDA) has approved deuruxolitinib 8-mg tablets for the treatment of adults with severe alopecia areata, Sun Pharmaceuticals Industries Limited announced in a press release. Deuroxolitinib is available from Sun Pharma under the name LEQSELVI. "
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati
- Weekly Cendakimab Dosing Effective in Reducing AD Severityhttps://practicaldermatology.com/news/weekly-cendakimab-dosing-effective-reducing-ad-severity/2467489/New research shows that cendakimab is safe and efficacious at certain dosing levels over a 16-week study period in patients with moderate-to-severe atopic dermatitis (AD). The study authors for the phase 2 trial included 221 adult patients with moderate-to-severe AD from the United States
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Dermaliq Therapeutics Announces Positive Topline Results from Phase 1b/2a Trial of Androgenetic Alopecia Treatmenthttps://practicaldermatology.com/news/dermaliq-therapeutics-announces-positive-topline-results-phase-1b2a-trial-androgenetic-alopecia-treatment/2467422/Dermaliq Therapeutics announced statistically significant topline data from a randomized, blinded, vehicle and comparator-controlled clinical phase 1b/2a trial in men with androgenetic alopecia (male pattern baldness, AGA) for its topical product candidate DLQ01, a prostaglandin F2α analog, based
- Taylor Fritz Partners with La Roche-Posay for Sun Safety Campaignhttps://practicaldermatology.com/news/taylor-fritz-partners-la-roche-posay-sun-safety-campaign/2467419/La Roche-Posay has partnered with professional tennis player Taylor Fritz to promote awareness of sun safety practices, according to a news release. Taylor Fritz, currently the highest-ranked American male tennis player, will serve as the sun safety spokesperson for La Roche-Posay to high